for thank and all afternoon, joining today. Good you Jamie. you, us Thank
few have year. when we accomplished at this our was global everything future we June. a and a We the in established earlier our One in last international Development was thrilled With main of headquarters goal an long-term vision step the this organization. Switzerland, build Zug, the Research toward highlight prospects gave growth years, as and strategy of accomplishing outlining we highlights quarter that I over Day to
us providing we pulmonary sotatercept has footing, a rare from disease by disease, therapies. been by our bolstered vision built paradigm-changing these aspire potentially of are building and REBLOZYL sclerosis-associated systemic position a sales the allowing a in solid leadership two to in to revenues As hypertension execute royalty financial pulmonary of Anchored on ACE-XXXX lung interstitial our on franchise. plan,
clinical the In to clinical rare enable rare sheet in space. our to supporting potential, or business our development capitalize pulmonary pulmonary plans development addition should disease, upon in opportunities stage us early balance
moment PH. to our I to potential research other as interest PAH distinct the WHO hypertension estimated develop superfamily continues or of significant one disease and like rare Beginning or patients Even an which a team would establish we more arterial explore a patients of pulmonary XX,XXX Acceleron. to sotatercept broadly as of disease. plans PAH, TGF-beta represents expect reviewing backbone Group areas Europe. pulmonary our with pulmonary multiple in spend a to at stages across now in with therapy in to and States hypertension affected with opportunity market United patients for sotatercept population the
III through of clinical a We STELLAR, are PAH and evaluating Phase ZENITH patient trials. in HYPERION population range sotatercept our
Phase registrational. we in PH pre- combined also who a post-capillary is patients heart X a develop Later with and We trial, to believe PH. there II fraction have preserved with the sotatercept opportunity this unique ejection left PH, the to specifically in form disease, substantially year, study initiate US trial CADENCE Group plan affected and of our CADENCE in to proof-of-concept the to XX,XXX patients population. latest this estimate, this patient believe Europe According by sotatercept's future adding more be to has in potential prospects. the are than Notably, we
in PAH PH with methodical disease. further opportunity potential takes and area, three XX.XXX by which evaluations expand is Europe. sotatercept exceptionally disease for sotatercept a This committing new group patients Acceleron Group approach. PH, in for to the an preclinical Lastly, we When US are also lung the market more would interstitial than conducting in
underlying has our disease translate II in This REBLOZYL, to dosing of maturation allowed when III led of apply to entering and rapidly establish that both from scientific scientific clinic move understanding positive, thalassemia of for insights is confirmatory in interest rationale these trial. MDS teams models in Early erythroid a approach used research disease Phase well-designed biology and Our the rationale full PAH. studies that clinical and inform first-in-class We proof-of-concept sotatercept into III to agent to approval recapitulate Phase for design space the a of trials. beta success fundamental develop to followed the by approvable to and animal Phase program guide us early medicine.
are the Jay SSc-ILD. PH, applying slide Group we methodology at two outlined to previous R&D into move advance on to which the into same I Day, and highlighted ACE-XXXX As
of superfamily sotatercept function, effective right the are PH. and notably PAH were was the in several key Importantly, hallmarks reverse In key shown with to associated with disease associated that doses. PH superfamily similarities Group signaling and vascular observed PH of diastolic levels two regard Improvements and heart and remodeling body. a also SSc-ILD, are with the disease pathology. share certain the hypertension In manifestations function to studies, and ventricular right signaling preclinical throughout at pulmonary left aberrant TGF-beta TGF-beta
to to kidney. typically In heart and are was studies, in in hallmark elevated reduce improvement levels an function. X shown lung, lung ACE-XXXX fibrosis, TGF-beta skin, significantly Specifically, preclinical the leading
creating of and among opportunity SSc-ILD lung fibrotic is the patients reminder, rare in the portfolio of As greater the an an leading disease to a of for estimate space. We in have even sclerosis. impact assets two addressable has a with pulmonary considerable XX,XXX death the interstitial systemic with population approximately Acceleron cause US patients Europe, disease in
opportunity perspective, of DMS in of billion from $X I us would nearly million in in for Acceleron. earlier, and $XXX covering annual our rate royalty XXX% As the more of royalties tiered mentioned sustained non-risk-adjusted have of than costs, program XXXX, more future mid-XXs on strong financial continued to rare than positioning and translate franchise put top low our revenues foundation the with pulmonary into a unique royalty a we the sales to estimated To REBLOZYL, for build growth. disease this
Moving REBLOZYL Europe Squibb REBLOZYL the now This Acceleron. net quarter with and of $XX.X of the ongoing and million. in $XX.X Bristol-Myers States million million sales to $XXX $XXX certain in launch. the countries royalties the of quarter, in royalties resulting in sales Acceleron for reported second to in in approximately first United million in compares approximately
uptake transition initial patient to through demand. launch bolus half new we as group the continue are patient the progress make with We underlying pleased product working the from of in the and first in in year, to earlier
as commercial treatment. driving and as growth on brand's appropriate joint on the teams focused their dosing this are reach in to Our REBLOZYL proper year to physicians MDS duration expanding patient journey, further beyond earlier of benefit maximize increased educating well patients and by
we the spread several from attributed center and impact increase facing we within COVID relief areas that the an weeks, during in seen have while experience the variant. some of increase second restrictions an the the Now hospitalizations to the related marketplace in quarter, cases in are in Delta did past few COVID
our for We are ability situation closely centers. its monitoring access on to treatment and patients effects certain the
end to period XX new the sotatercept course a seeing Conference from in SPECTRA improvement extension therapies of ATS the are reduction including markets distance, on points, the trial the Additionally, reimbursement. to PULSAR the trial on Thoracic consistent weeks. XXXX, responses the II stable uptake in efficacy the data of as and class experienced PAH-specific launches for with over International when of open-label Phase treated we background sotatercept extension trial. with or improved or II PULSAR strong in American and ex-US Beginning and this the NT-proBNP, patients walk presentation anticipate with we functional new receive multiple Phase six-minute highlights, Equally we up they Society market in year from trial, returned exciting, open-label
top patients the weeks with of rerandomized sotatercept on experienced period. treatment receiving placebo improvements therapy trial, the clinical therapies initial in background to during weeks during Additionally, XX first XX after placebo-controlled of those background plus to the stable consistent XX seen receive
reported results, the number key We interim on of sotatercept trial. II assessing Phase measures. SPECTRA effect to of Turning a
at peak efficacy, end the As by the points, at well as end in week cardiopulmonary investigators test improvements content. measured arteriovenous and of as secondary total baseline primary workload including ventilatory and uptake, in of XX, invasive oxygen point range exercise recorded oxygen
an XX.X from In of in distance meters data by increased whom average available. to week XX addition, nine were six-minute walk baseline patients for
to Sotatercept was tolerated We consistent generally from well both updates events studies longer-term with adverse providing presented with generally studies XXXX. previously forward in look in data. both
the additional plus the pulmonary results, the II the patients Congress, results BEYOND we were to luspatercept, reported in development the from to partner, well luspatercept achieved patient baseline six hand ways the correlated with XX we'll affected tolerated. luspatercept the And hemoglobin. at call XX.X% abstracts known to take As the as the the over patient-reported to per adult In with we arm we best the patients of in June, the anemia. in European Squibb, McLaughlin, Changes at supportive then during hemoglobin with of in Phase Congress, top to perspective, compared achieving CFO, luspatercept, increase Hematology evaluating questions. Kevin? patients presidential REBLOZYL, to weeks increases outcomes like be primary According nontransfusion-dependent also of care of our pipeline, XXXX many by the to at beta-thalassemia. with that, primary expand study treated our into advance symposium the From during available end of least presented point. continue XX in end collaboration to a Association evaluate from our X% Bristol-Myers would and populations point Virtual global one and placebo financials, to generally Kevin your review gram I safety of deciliter an which was also
